BSX
Boston Scientific Corp.
stock NYSE

What does this have to do with BSX?

This has nothing to do with the cyber attack. BSX stock had already lost \~50% of its value between December 2025 and July 2026, and the cyber event occurred at the end of August.
The story is this -> The huge growth of BSX stock between 2023 and 2026 was driven by success in the EP space, namely with the watchman device and PFA technology. However, new clinical evidence has resulted in less physician referrals for watchman procedures, and competition (J&J, Abbott, etc) has caught up in the PFA space. This has led to a significant reduction in revenue for Boston’s most important business unit, so much so that they announced a $800 million restructure of their EP business back in July.
TLDR: The stock price fell due to significant losses in their EP business, not the cyber attack.

BSX is an excellent representation of the hot hand fallacy.

[https://finance.yahoo.com/healthcare/articles/why-bsx-stock-lost-more-163125666.html](https://finance.yahoo.com/healthcare/articles/why-bsx-stock-lost-more-163125666.html)

I followed this company for a while when I was getting my feet wet with learning about selling options (simple calls and puts). They were pretty consistent, always beat quarterly earnings, medical product lines seemed balanced, had an occasional acquisition, no drastic leadership changes, etc. I made a few bucks and was happy. But it seemed like after their long time CFO announced retirement mid 2025, it seems like a turning point in a way. There was a recent acquisition, Penumbra, Inc. that cost a lot of money but it got approved. There were also some revisions to their outlook (I forget if it was for 2026 initially or late 2025 first...) but that seemed to have a negative reaction from the market. Not to mention they also had a recent cyber attack and it was announced rather quickly that this would have a negative impact on their upcoming earnings.

Those are the cliff notes at least lol the 4hr chart looks like it's coming back to the mid to low 40s... :(

Not quite true. I work at BSX. As far as I've heard all cyber incidents were resolved and service resumed in full about a week and a half ago. The global application I manage was brought back online on the 4th. 
Still a bad hit to production and sales but it was a monumental effort internally to gut and rebuild affected IT infrastructure over two weeks. 

"People sell stock for a dozen reasons, but they generally buy it for one."
Jeff Green bought $150M of TTD around $24 in March. It got down to the $12's and is now $14.
"What actually happened to BSX this year? "
What happened to a lot of medtech. It's been a lousy year for a lot of names - look at ISRG, GEHC, etc. BSX cut guidance twice already this year, you've had rising competition and other issues. A lot of these names were also not exactly cheap to begin with and the series of concerns caused a considerable re-rating lower.
IMHO, selectively buying a little of this sort of thing is certainly fine, but the problem IMO becomes people pile into stuff like this that's down a lot and then it doesn't turn around right away while all the stuff that is popular continues to be popular and they quickly lose patience. There was someone recently who has piled into NKE because "well, it's Nike and it's got to turn around right?" "NKE can't go below 40" becomes "NKE can't go below 35." Meanwhile, they're not looking at the fact that much of the industry is struggling, which doesn't exactly help matters.

On 3 August the CEO, Mike Mahoney, bought 186,240 shares on the open market at about $48. That's roughly $9M of his own money. Three directors bought in the same few weeks.
These weren't plan trades or option exercises. Plain open-market purchases. People sell stock for a dozen reasons, but they generally buy it for one.
Worth saying they're already underwater. The stock is about 10% below where he paid.
What actually happened to BSX this year? I know the chart better than I know the story, and I'd rather hear it from someone who follows medtech

I'm seeing 90%-100%+ IV on some strikes for PEN a couple of months out. As the historical vol is very low (<20%) something seems to be brewing. But I can't find anything in the news, other than the BSX merger kind of failed. Any clue?

What does this have to do with BSX?

This has nothing to do with the cyber attack. BSX stock had already lost \~50% of its value between December 2025 and July 2026, and the cyber event occurred at the end of August.
The story is this -> The huge growth of BSX stock between 2023 and 2026 was driven by success in the EP space, namely with the watchman device and PFA technology. However, new clinical evidence has resulted in less physician referrals for watchman procedures, and competition (J&J, Abbott, etc) has caught up in the PFA space. This has led to a significant reduction in revenue for Boston’s most important business unit, so much so that they announced a $800 million restructure of their EP business back in July.
TLDR: The stock price fell due to significant losses in their EP business, not the cyber attack.

BSX is an excellent representation of the hot hand fallacy.

[https://finance.yahoo.com/healthcare/articles/why-bsx-stock-lost-more-163125666.html](https://finance.yahoo.com/healthcare/articles/why-bsx-stock-lost-more-163125666.html)

I followed this company for a while when I was getting my feet wet with learning about selling options (simple calls and puts). They were pretty consistent, always beat quarterly earnings, medical product lines seemed balanced, had an occasional acquisition, no drastic leadership changes, etc. I made a few bucks and was happy. But it seemed like after their long time CFO announced retirement mid 2025, it seems like a turning point in a way. There was a recent acquisition, Penumbra, Inc. that cost a lot of money but it got approved. There were also some revisions to their outlook (I forget if it was for 2026 initially or late 2025 first...) but that seemed to have a negative reaction from the market. Not to mention they also had a recent cyber attack and it was announced rather quickly that this would have a negative impact on their upcoming earnings.

Those are the cliff notes at least lol the 4hr chart looks like it's coming back to the mid to low 40s... :(

Not quite true. I work at BSX. As far as I've heard all cyber incidents were resolved and service resumed in full about a week and a half ago. The global application I manage was brought back online on the 4th. 
Still a bad hit to production and sales but it was a monumental effort internally to gut and rebuild affected IT infrastructure over two weeks. 

"People sell stock for a dozen reasons, but they generally buy it for one."
Jeff Green bought $150M of TTD around $24 in March. It got down to the $12's and is now $14.
"What actually happened to BSX this year? "
What happened to a lot of medtech. It's been a lousy year for a lot of names - look at ISRG, GEHC, etc. BSX cut guidance twice already this year, you've had rising competition and other issues. A lot of these names were also not exactly cheap to begin with and the series of concerns caused a considerable re-rating lower.
IMHO, selectively buying a little of this sort of thing is certainly fine, but the problem IMO becomes people pile into stuff like this that's down a lot and then it doesn't turn around right away while all the stuff that is popular continues to be popular and they quickly lose patience. There was someone recently who has piled into NKE because "well, it's Nike and it's got to turn around right?" "NKE can't go below 40" becomes "NKE can't go below 35." Meanwhile, they're not looking at the fact that much of the industry is struggling, which doesn't exactly help matters.

On 3 August the CEO, Mike Mahoney, bought 186,240 shares on the open market at about $48. That's roughly $9M of his own money. Three directors bought in the same few weeks.
These weren't plan trades or option exercises. Plain open-market purchases. People sell stock for a dozen reasons, but they generally buy it for one.
Worth saying they're already underwater. The stock is about 10% below where he paid.
What actually happened to BSX this year? I know the chart better than I know the story, and I'd rather hear it from someone who follows medtech

I'm seeing 90%-100%+ IV on some strikes for PEN a couple of months out. As the historical vol is very low (<20%) something seems to be brewing. But I can't find anything in the news, other than the BSX merger kind of failed. Any clue?